Loading...
Loading...
LIPO| Name | Value |
|---|---|
| Revenues | 145.9K |
| Cost of Revenue | 0.1K |
| Gross Profit | 145.8K |
| Operating Expense | 1,363.5K |
| Operating I/L | -1,217.7K |
| Other Income/Expense | 25.8K |
| Interest Income | 25.8K |
| Pretax | -1,191.8K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -1,191.8K |
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company specializing in reformulating active agents in generic drugs to develop optimized formulations for various applications. The company's primary focus is on developing drugs such as LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis, and LP-310, a formulation for the treatment of oral lichen planus. By leveraging reformulations of existing generic drugs, Lipella Pharmaceuticals aims to create innovative drug solutions for specific medical conditions, driving revenue through the development and commercialization of these optimized drug formulations.
